BIRC3 (also termed cIAP2) is a member of the inhibitor of apoptosis (IAP) protein family, characterized by:
Caspase inhibition: Direct suppression of caspase-3 and caspase-7 activation to block apoptosis .
Therapeutic resistance: Upregulation in glioblastoma (GBM) cells after temozolomide (TMZ) chemotherapy or radiation therapy (RT), correlating with reduced patient survival .
Signaling node: Acts downstream of PI3K-alpha and STAT3 pathways, which drive its expression during RT-induced stress in GBM .
The PrecisionAb™ BIRC3 antibody (Clone K01/2A8) is validated for:
| Application | Dilution Range | Target Species | Molecular Weight |
|---|---|---|---|
| Western Blotting | 1:1000 | Human | ~74 kDa |
| Immunoprecipitation | Not specified | Human | - |
Source: Product specifications for anti-BIRC3 antibody .
Key features:
Specificity: Recognizes recombinant human BIRC3 (amino acids 1–604) .
Functional relevance: Used to study BIRC3’s role in NF-κB signaling and apoptosis evasion in cancers like glioblastoma and oral squamous cell carcinoma .
Glioblastoma:
Mechanistic drivers:
RCAS-PDGFB-induced tumors with BIRC3 overexpression show 70% fewer caspase-3-positive cells compared to controls (P < 0.0001) .
Cadmium exposure in renal cells reduces BIRC3 levels, increasing active caspase-3 and apoptosis .
Prognostic marker: Low BIRC3 expression correlates with improved 5-year survival in GBM patients .
Therapeutic target: PI3K-alpha inhibitors (e.g., PIK-75) sensitize BIRC3-overexpressing GBM cells to TMZ/RT .
Drug development: BIRC3-specific inhibitors are under investigation for oral squamous cell carcinoma and colorectal cancer .